Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that early-onset androgenetic alopecia, especially with a vertex pattern, may be an independent risk factor for cardiovascular disease and metabolic syndrome in men.

This analysis suggests that the reported association between androgenetic alopecia and severe COVID-19 may be overstated, as prevalence rates in patients match expected levels based on prior studies.

In this case report, researchers observed that a 35-year-old male with alopecia universalis achieved full regrowth of scalp, eyebrow, and facial hair with oral upadacitinib treatment after previous therapies failed to provide lasting relief.

In this study, non-obese females with early-onset androgenetic alopecia showed higher total cholesterol, LDL cholesterol, triglycerides, and atherogenic index, and lower HDL cholesterol compared to controls, suggesting an association with adverse cardiovascular risk factors.

This article outlines management guidelines for androgenetic alopecia, highlighting that continued treatment with medications like finasteride or minoxidil typically halts progression and improves hair condition in most mild to moderate cases.

This review found that recent innovations, such as topical medications, lasers, and microneedling, have shown significant reductions in androgenetic alopecia indicators, but more research is needed to refine treatments.

This comprehensive review analyzes androgenetic alopecia treatments, discussing the mechanisms, costs, efficacy, and safety of FDA-approved drugs like minoxidil and finasteride, as well as newer non-FDA-approved options that have shown effectiveness across various studies.

This study found that circAGK was highly expressed in AGA patients and promoted dermal papilla cell apoptosis, suggesting it as a potential target for treating androgen alopecia.

This study found that in AGA, the risk allele at locus 2q35 alters WNT10A expression through EBF1, suggesting a potential androgen-dependent regulatory mechanism.

People with androgenetic alopecia may have a higher risk of peripheral venous disorders.

This study reported no significant statistical difference in insulin resistance or QUICKI levels between reproductive women with androgenetic alopecia and age-matched controls.

This study highlights the potential of polymeric micelles in enhancing the targeted delivery and efficacy of treatments for androgenetic alopecia, by offering improved retention on the scalp, extended release, and reduced systemic side effects compared to conventional therapies like minoxidil and finasteride.

This study evaluated the quality of androgenetic alopecia guidelines using the AGREE II instrument and found the European guideline to be the highest-rated, while American guidelines required modifications.

This review discusses the physiopathology of androgenetic alopecia and evaluates various traditional and emerging treatments, reporting no new clinical results but highlighting the need for enhanced treatment strategies.

This case report describes androgenetic alopecia in two young siblings, highlighting its occurrence in children and suggesting a possible familial pattern given their mother's similar condition.

This study found significant differences in serum lipoprotein (a) and triglyceride levels between men with androgenetic alopecia and those with normal hair, suggesting a need for dermatologists to monitor lipid profiles in these patients.

This study developed a testosterone-induced androgenetic alopecia model in BALB/c mice, finding that a 0.075 ml testosterone injection best replicated the dermal and hair follicle conditions of AGA patients, providing a promising tool for future drug testing and research into AGA therapies.

This study outlines a hair regrowth treatment targeting hair follicle stem cells, 5-alpha reductase pathway, and microinflammation using PDGF and VEGF, but reports no clinical results.

This study concluded that ACT injections, alone or combined with finasteride, have significant therapeutic effects and safety in treating androgenic alopecia, with promising clinical potential.

This study provides evidence that a polygenic component contributes to the heritable risk for androgenetic alopecia, indicating the need for further research to identify the complex biological pathways involved.

This study examined the relationship between early-onset androgenetic alopecia and metabolic syndrome, but the abstract does not report specific findings.

This study found that certain trichoscopic features like white peripilar sign, yellow dots, and scalp pigmentation are positively correlated with the severity of androgenetic alopecia in Chinese patients.

This study focused on developing and validating standardized methods to reliably assess hair growth and scalp health in androgenetic alopecia, finding significant differences in hair parameters such as vellus and terminal hair counts, density, and thickness between affected and standardized areas.

In this study, researchers at a tertiary care center reported a significant correlation between severe COVID-19 cases and the presence of androgenic alopecia, suggesting that androgen receptor expression may influence COVID-19 severity.

This review discusses advances in molecular biology and genetics related to androgenetic alopecia and reports no new clinical results.

Androgenetic alopecia, a common hair loss condition, can affect mental health and there are various medical treatments available for it.

This review outlines that minoxidil (topical and oral) and 5α-reductase inhibitors are the most effective treatments for androgenetic alopecia, with additional therapies like platelet-rich plasma and hair transplantation enhancing results, emphasizing the need for individualized, combination approaches.

This study observed that patients with alopecia areata often have a T-cell receptor repertoire in skin lesions that suggests a specific antigen-driven immune response may be important in the disease's pathogenesis.

This study found that ACOD1 deficiency in dermal papilla cells promotes mitochondrial dysfunction and contributes to cellular senescence in androgenetic alopecia, suggesting ACOD1 as a potential therapeutic target and 4-octyl itaconate as a promising treatment option for AGA.

In this retrospective study, researchers identified a previously undetected pattern of hair regrowth resembling androgenetic alopecia in 13 of the 1604 alopecia areata cases examined.